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Intracellular tracing of amyloid 
vaccines through direct fluorescent 
labelling
Matthew Mold  , Manpreet Kumar, Ambreen Mirza, Emma Shardlow & Christopher Exley
Alzheimer’s disease is a debilitating neurodegenerative condition that progressively causes synaptic 
loss and major neuronal damage. Immunotherapy utilising Aβ as an active immunogen or via passive 
treatment utilising antibodies raised to amyloid have shown therapeutic promise. The migratory 
properties of peripheral blood-borne monocytes and their ability to enter the central nervous system, 
suggests a beneficial role in mediating tissue damage and neuroinflammation. However, the intrinsic 
phagocytic properties of such cells have pre-disposed them to internalise misfolded amyloidogenic 
peptides that could act as seeds capable of nucleating amyloid formation in the brain. Mechanisms 
governing the cellular fate of amyloid therefore, may prove to be key in the development of future 
vaccination regimes. Herein, we have developed unequivocal and direct conformation-sensitive 
fluorescent molecular probes that reveal the intracytoplasmic and intranuclear persistence of amyloid 
in a monocytic T helper 1 (THP-1) cell line. Use of the pathogenic Aβ42 species as a model antigen in 
simulated vaccine formulations suggested differing mechanisms of cellular internalisation, in which 
fibrillar amyloid evaded lysosomal capture, even when co-deposited on particulate adjuvant materials. 
Taken collectively, direct fluorescent labelling of antigen-adjuvant complexes may serve as critical tools 
in understanding subsequent immunopotentiation in vaccines directed against amyloidosis and wider 
dementia.
Alzheimer’s disease (AD) is the most prevalent form of dementia manifesting neurologically and symptomati-
cally arising through the loss of spatial and short-term memory. Thereafter, the progressive nature of the disease 
ensues through complete and irreversible loss of executive function1. The most well characterised mechanism 
associated with neurodegeneration is the amyloid cascade hypothesis of AD. It postulates that the accumulation 
of the amyloid-β (Aβ) peptides, Aβ40 and Aβ42 through processing of the amyloid precursor protein (APP) or 
their decreased removal in the brain result in the formation of aggregated insoluble amyloid plaques2. Through 
a cascade of deleterious effects, the amyloid plaques formed are suggested to break down releasing neurotoxic 
oligomeric species of Aβ, resulting in synaptic loss and neuronal damage1,3,4.
While this theory has been disputed with calls for its reassessment, current consensus supports the hypothesis 
that the accumulation of the Aβ peptides in vivo, contributes to the pathogenesis of both familial and sporadic 
forms of AD1,5. The recapitulation of the mechanisms underlying the onset of AD is most commonly achieved 
through the use of transgenic mouse models of the disease state6,7. These animals typically overexpress mutant 
human forms of APP and the presenilin genes, triggering the progressive development of many of the pathologi-
cal hallmarks of AD. Within these transgenic models, APP is overexpressed and is first cleaved by β- followed by 
γ-secretase, releasing neurotoxic Aβ peptides into the extracellular space.
In addition, Aβ is thought to be transported in an unknown manner from the periphery to the brain as seeds 
capable of corrupting host Aβ that subsequently deposits as senile plaques8. In spite of the extensive use of trans-
genic animal models, most often they best reflect rare familial forms of AD that may lack the large-scale loss of 
neurons that follows cognitive decline9. While in vivo models have provided insight into the pathogenesis of AD, 
successful therapeutic strategies stemming from their use have thus far, remained elusive. For example, vaccina-
tions using the Aβ42 peptide in active immunisation were shown to be effective in both preventing and reversing 
AD pathogenesis in transgenic mice that overexpressed mutant human APP, in which the normal valine at 717aa 
was replaced with a phenylalanine residue6. However, while these early studies sparked widespread interest it was 
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later found that the use of Aβ42 in immunisation regimes triggered excessive inflammation presenting clinically 
as encephalitis caused by the activation of specific inflammatory T cells10–14.
Aβ in immunotherapy utilising active immunisation or passive immunisation of patients using antibodies 
raised against Aβ have shown therapeutic promise, most notably through reducing the neuropathological hall-
marks of AD6,15. A recent clinical trial utilising passive immunisation of the monoclonal antibody against aggre-
gated Aβ, aducanumab, demonstrated reductions in both soluble and fibrillar forms of cortical amyloid and a 
reduction in clinical decline15. Phase III clinical trials of the drug are currently underway to uncover new treat-
ment regimes15. Overall, immunisation trials continue to highlight the potential of vaccines directed against Aβ 
in the effective clearance of AD neuropathology.
Recent efforts have focused on the use of three-dimensional (3D) cellular models of AD that were proposed 
to fully recapitulate Aβ and tau pathology in a single model, thereby overcoming some of the limitations encoun-
tered in the use of single transgenic mouse models16. Whilst this study was able to demonstrate the presence 
of amyloid deposits in 3D cell cultures, the study did not provide unequivocal evidence for the deposition of 
amyloid in a β-pleated sheet conformation, owing to the staining methodologies employed. Paradoxically ques-
tions currently remain into how the use of these models will be translated into successful clinical interventions 
against AD and dementia. This is most probably explained by the lack of knowledge concerning the cellular fate of 
amyloidogenic species in vivo and why normal cellular autophagy processes fail to break down these neurotoxic 
deposits17,18.
Attempts to monitor the extracellular deposition and the subsequent cellular uptake of Aβ, have frequently 
made use of immunolabelling. Therein, antibodies to Aβ containing a fluorescent tag or immunogold particles 
of a fixed size, are regularly used to demonstrate intracellular amyloid via fluorescence and transmission electron 
microscopy (TEM) approaches respectively19,20. The specificity of detection in immunolabelling is based on the 
binding of the primary antibody, of which the paratope is typically directed towards short chain fragments of the 
full-length peptide21. As such, these constructs are able to bind amyloid irrespective of the peptide morphology, 
rendering them ineffective in tracing the conformational changes of amyloidogenic peptides in complex biolog-
ical systems.
Commercially available fluorochromes may also be conjugated directly to amyloid either through binding to 
the N-terminus of the amino acid chain, or as an amine reactive conjugate21,22. Use of a fluorochrome ensures an 
intense fluorescence signal with well-defined excitation and emission properties. However, unlike fluorophores 
that produce a fluorescence emission only when bound to amyloidogenic peptides, fluorochromes produce flu-
orescence regardless of whether coordinated or tagged to amyloid. Therefore, it is unclear from these studies as 
to the conformation of short-chain amyloidogenic species, whether identified intracellularly or deposited extra-
cellularly in simulated animal or cell-based models of vaccination. In order to distinguish between distinct con-
formational states of amyloid, studies have made use of the isolation and subsequent labelling of amyloid species 
including monomeric, oligomeric, intermediate protofibril and mature β-pleated sheets of the peptide20,21. The 
inherent ability of amyloid to self-aggregate into a conformation rich in β-sheet structure in vivo however, casts 
doubt on the structural stability of intermediate amyloid species, especially when internalised in complex cellular 
environments4,19,20.
Thioflavin S (ThS) and thioflavin T (ThT) have received frequent use in their ability to identify amyloid depos-
its by interacting with the cross-β sheet structure of amyloid fibrils23. ThT is a benzothiazole dye and ThS is a 
sulfonated derivative of ThT with similarities to the sulfonated azo dye, Congo red. The inherent lack of selectivity 
of Congo red binding to amyloid as revealed under fluorescence excitation, however, has impeded its use in the 
intracellular monitoring of amyloidogenic species23,24. Therefore, increasing numbers of studies have used ThT to 
detect amyloid aggregation within solution, especially when using synthesised or truncated peptides24–26.
Interestingly, these classical staining methods for amyloid are often used only to confirm the presence of amy-
loid, conjugated to its tagged fluorescent label. Herein, we establish direct fluorescent-based labelling methods of 
Aβ42, allowing for the conformation of intracellular amyloidogenic species to be assessed in an in vitro T helper 
1 (THP-1) cell line. Through the complementary use of TEM, the unequivocal cellular uptake and localisation of 
amyloid co-adsorbed to clinically relevant adjuvant complexes are demonstrated. These approaches shed light on 
the cellular fate of Aβ in a simulated cell-based model of vaccination, supporting cellular mechanisms of amyloid 
presentation in current and future vaccine development.
Results
Assessment of the cellular uptake of a model amyloid antigen via direct fluorescent label-
ling. Thioflavin T (ThT) fluorescence of the amyloidogenic Aβ42 peptide was first assessed in R10 cell culture 
medium, to ensure the formation of mature amyloid fibrils in treatment conditions compatible with subsequent 
T helper 1 (THP-1) cell culture (see Supplementary methods). Aβ42 prepared at 4 μM and incubated over 24 h at 
37 °C produced a 64.8% increase in fluorescence intensity measured at 482 nm (13.07 ± 0.34, mean ± SD, n = 3), 
above background of R10 cell culture medium only (4.60 ± 0.85, mean ± SD, n = 3). Amyloid fibril formation 
propagating as β-sheets at the concentrations stated herein was therefore confirmed in R10 media.
The assessment of the cellular uptake of Aβ42 was investigated initially in the absence of added aluminium 
based adjuvant (ABA) nanomaterials. In order to assess cellular uptake of β-pleated sheets of amyloid formed 
under these conditions, the use of ThT as a pre-labelling reagent (20 μM) was first assessed in treatments contain-
ing 8 μM of the peptide only. Aβ42 pre-incubated for 24 h in R10 medium containing ThT and co-cultured (1:1) 
with THP-1 cells for 1 h (37 °C, 5% CO2), revealed the cellular uptake of amyloid in a β-sheet conformation as 
identified through a green fluorescence emission (482 nm) contained in cell cytosol (Fig. 1). ThT-reactive amy-
loid was identified following 1 h incubation, as evidenced via punctate green fluorescence in focal deposits at the 
periphery of THP-1 cells. Cellular uptake of amyloid fibrils was also observed in identical experiments over 1, 3, 6 
and 24 h (see Supplementary Fig. 1). THP-1 cells co-cultured under identical conditions in the absence of added 
www.nature.com/scientificreports/
3Scientific REpoRTS |  (2018) 8:2437  | DOI:10.1038/s41598-018-20845-9
amyloid produced a uniform weak green fluorescence emission that was found to increase in intensity upon pro-
longed incubation over 24 h in the presence of ThT (see Supplementary Fig. 2).
The complementary use of transmission electron microscopy confirms the cellular internali-
sation of fibrillar amyloid. In order to confirm the cellular internalisation of amyloid, THP-1 cells were 
co-cultured under identical conditions over 1–24 h, of which cell sections (90 nm) were negatively stained with 
uranyl acetate (2% w/v). Pre- osmium tetroxide and lead citrate staining were omitted to allow for greater clarity 
in the detection of potential intracellular amyloid. Aβ42 aged for 24 h in R10 media and co-cultured with THP-1 
cells (at 4 μM) for 1 h, revealed negatively stained deposits of intracellular amyloid fibrils as plaque-like aggregates 
in cell cytosol (Fig. 2a,e and i). Intracellular clustering of negatively stained fibrils was also identified within the 
cytoplasm of THP-1 cells following 3 (Fig. 2b,f and j) and 6 h (Fig. 2c,g and k) incubation at 37 °C. Of those fibril-
lar deposits identified, no aggregates of amyloid were found enclosed in vesicular-like structures in the cytoplasm 
of THP-1 cells.
At every time point investigated thereafter over 24 h, electron-dense deposits of negatively stained amyloid 
fibrils were found internalised in THP-1 cells that varied in size dramatically. Mature amyloid fibrils exhibit-
ing classical negative staining were readily identified following 24 h co-culture with cells (Fig. 2d,h and l). 
Interestingly, negatively stained amyloid fibrils of morphology not dissimilar to intracytoplasmic Aβ42 were also 
found deposited within nuclei of THP-1 cells (see Supplementary Fig. 3). Therefore, TEM of THP-1 cells cultured 
in the presence of a model Aβ42 peptide antigen confirmed the presence and intracellular persistence of amyloid 
β-sheets.
Direct fluorescent labelling reveals the cellular internalisation of simulated amyloid adju-
vant vaccines. The direct fluorescent labelling of a model Aβ42 amyloid antigen (4 μM) and its co-adsorbed 
ABA (25.0 μg/mL) utilised the fluorophores ThT and lumogallion, respectively. Experiments monitoring cellu-
lar uptake of simulated vaccine treatments utilised 20 and 100 μM of the respective fluorophores, throughout. 
Initially, both fluorescent dyes were added to simulated vaccine treatments at T = 0. All pre-incubated vaccine 
treatments (24 h) co-cultured 1:1 with THP-1 cells, emitted positive intracellular lumogallion (orange) and ThT 
fluorescence (green). The broad emission of lumogallion complexed to particulate ABA was, however, found to 
pass through the longpass fluorescence filter used to collect fluorescence for ThT–reactive amyloid (482 nm), ren-
dering adjuvant and antigen difficult to distinguish from one another (see Supplementary Fig. 4).
In order to isolate the fluorescence of ThT from lumogallion, a single bandpass filter was used (see 
Supplementary Fig. 5). As such, only emitted light of wavelength 470–500 nm was allowed to pass through to the 
detector, encompassing the ThT emission maxima of 482 nm when complexed to amyloid. Fluorescence micros-
copy of aged Aβ42 (29 μM), prepared as sections (5 μm) and stained with 1 mM ThT for 24 h, revealed a blue versus 
a green fluorescence emission under single and long bandpass filters, respectively (see Supplementary Fig. 6). 
While specificity of ThT to mature amyloid fibrils was observed under both filter types, the fluorescence intensity 
was found to be weaker under single bandpass emission. However, it was found that fluorescence emission for 
lumogallion and ThT bound to adjuvant and antigen respectively, could be successfully isolated thereby allowing 
for their intracellular identification within THP-1 cells (see Supplementary Fig. 5). Therefore, single bandpass 
emission filters were used throughout for the detection of intracellular fluorescence of antigen and adjuvant for-
mulations in simulated vaccine treatments.
Figure 1. Representative fluorescence microscopy of whole THP-1 cells cultured for 1 h in R10 medium 
containing 10 μM thioflavin T (ThT) in the presence of 4 μM Aβ42. Cells were fixed in 4% w/v PFA, washed in 
50 mM PIPES buffer, pH 7.4 before mounting with Fluoromount™ (Sigma Aldrich) on poly-lysine coated slides. 
ThT fluorescence (green) is depicted (Olympus long bandpass U-WMBV2 filter cube) with the magnified insert 
denoted (*) of which the bright-field image has been overlaid. White arrows highlight the presence of ThT-
reactive deposits within THP-1 cells. Magnification X 1000, scale bar: 20 μm.
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Optimisation of pre-labelling simulated vaccine formulations focused upon obtaining distinguishable fluo-
rescence of amyloid co-adsorbed to its ABA, over the shortest possible time period. Simulated vaccine treatments 
containing 8 μM Aβ42 in the presence or absence of 25.0 μg/mL of an ABA (Alhydrogel®, Adju-Phos® or Imject™ 
Alum) were first incubated for 24 h, prior to their addition to THP-1 cells. Pre-incubated treatments were subse-
quently plated 1:1 with cells for 24 h, of which the fluorophores ThT and lumogallion were simultaneously added 
only 3 h prior to fixation, in order to minimise their influence on the cellular uptake of Aβ42 and co-adsorbed 
ABA.
THP-1 cells co-cultured in the presence of pre-labelled Aβ42 only produced a blue fluorescence emission 
within the cytoplasm of THP-1 cells. In the absence of added ThT, THP-1 cells co-cultured under identical con-
ditions produced a uniform blue fluorescence emission of lower relative intensity (see Supplementary Fig. 7). 
Simultaneous pre-labelling of Aβ42 in the presence of Alhydrogel® revealed an intracellular orange fluorescence 
emission under the lumogallion fluorescence channel, indicative of particulate loading in cell cytosol (Fig. 3a). 
Upon illumination of the same population of whole cells under the ThT fluorescence channel, an intense intracel-
lular blue fluorescence was observed (Fig. 3b). Merging of both lumogallion and ThT fluorescence filter channels 
for THP-1 cells co-cultured with Aβ42 adjuvanted with Alhydrogel® demonstrated the co-localisation of amyloid 
and adjuvant material, of which merging of both signals resulted in a pink-purple fluorescence emission (Fig. 3c). 
Furthermore, overlaying of the bright field image confirmed that ThT and lumogallion reactive material was 
confined to THP-1 cells (Fig. 3d).
For those cells co-cultured with vaccine treatments containing Aβ42 in the presence of Imject™ Alum, 
lumogallion-reactive particulates were identified in cell cytosol via an intensive orange fluorescence emission 
(Fig. 3e). ThT-reactive material was additionally identified intracellularly via the observation of a blue fluo-
rescence emission confined to THP-1 cells (Fig. 3f). As with cells treated with amyloid and adjuvanted with 
Alhydrogel®, both lumogallion and ThT fluorescence was found co-localised in the cytoplasmic compartment 
of cells (Fig. 3g). Merging of bright field and fluorescence channels indicated that ThT and lumogallion positive 
fluorescence was confined to THP-1 cells (Fig. 3h).
Simulated Aβ42 vaccine treatments adjuvanted with 25.0 μg/mL Adju-Phos® and co-cultured with THP-1 
cells, produced an intensive and uniform intracellular orange fluorescence emission, under the lumogallion 
filter channel. Due to the inability to distinguish lumogallion reactive material in whole cells, the concentra-
tion of Adju-Phos® was halved in cell culture conditions. Subsequent analyses of co-cultured THP-1 cells high-
lighted the presence of a punctate intracellular orange lumogallion-reactive fluorescence emission (Fig. 3i). 
Figure 2. Representative electron micrographs from TEM of Spurr resin-sectioned (100 nm sections) THP-1 
cells co-cultured with 4 μM Aβ42 in R10 medium containing 10 μM thioflavin T (ThT) for (a,e and i) 1, (b,f 
and j) 3, (c,g and k) 6 or (d,h and l) 24 h. Cell resin-sections were stained for 20 min with 2% w/v ethanolic 
uranyl acetate, rinsed with 30% v/v ethanol followed by ultrapure water. Grids containing sections were allowed 
24 h drying time prior to analysis via TEM. Inserts show close-ups of intracellular negatively stained amyloid 
deposits and the red arrows highlight their presence within the respective cell images (e–h). A further example 
of intracellular negatively stained amyloid fibrils observed at 1, 3, 6 and 24 h, is also depicted (i–l). Magnification 
& scale bars: (a and c). X 10 K, 2 μm, (b) X 12 K, 2 μm, (d) X 8 K, 2 μm, (e–h) X 60 K, 0.5 μm & (i–l) X 100 K, 
0.2 μm, respectively.
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A blue fluorescence emission was also observed in identical cells under the ThT fluorescence channel and in 
close proximity to those structures producing lumogallion fluorescence (Fig. 3j). Interestingly ThT fluorescence 
was identified infrequently and of a lower intensity in comparison to those cells co-cultured in the presence of 
Alhydrogel® and Imject™ Alum, respectively. Merging of fluorescence channels revealed the close proximity of 
ThT and lumogallion fluorescence within the cytoplasm of THP-1 cells (Fig. 3k), of which overlaying of the bright 
field image confirmed their co-deposition in cells (Fig. 3l).
Confirmation of the cellular internalisation of amyloid and aluminium based adjuvant mate-
rials via transmission electron microscopy. The complementary method of TEM was performed in 
addition to fluorescence microscopy, in order to support the observations of intracellular Aβ42 co-adsorbed to its 
respective ABA. THP-1 cells were co-cultured with simulated amyloid vaccines under near-identical conditions 
and pre-labelling regimes, of which the ABA concentration was maintained at 50.0 μg/mL across treatment con-
ditions. This concentration of ABA has proven optimal in our previously published studies of adjuvant uptake in 
a THP-1 cell line27,28 and hence, was selected herein.
THP-1 cells co-cultured with simulated amyloid vaccines adjuvanted with Alhydrogel® revealed 
semi-crystalline and electron dense needles found solely within vesicular-like compartments within cell cyto-
plasm (Fig. 4a). Higher magnifications revealed negatively stained amyloid fibrils found deposited within cell 
cytosol. Interestingly, fibrillar deposits of apparent amyloid were identified both in the absence and presence 
of co-deposited needles of the adjuvant (Fig. 4d). Although rarely observed, negatively stained amyloid fibrils 
were found localised in cell nuclei, as with those experiments performed in the presence of the peptide only 
(see Supplementary Fig. 3). THP-1 cells co-cultured in simulated vaccine treatments containing Imject™ Alum, 
demonstrated the intracellular presence of large amorphous plate-like particulates of the adjuvant, spanning sev-
eral microns in width. Those electron-dense aggregates identified were contained in vesicular-like compartments 
and found solely within the cytoplasm of THP-1 cells (Fig. 4b). Negatively stained amyloid fibrils were observed 
only in the cell cytoplasm of THP-1 cells loaded with particulate adjuvant. The direct co-localisation of fibrillar 
amyloid and amorphous plates of particulate adjuvant material were clearly identified via negative staining with 
uranyl acetate (Fig. 4e).
Figure 3. Representative fluorescence microscopy of whole THP-1 cells cultured for 24 h in R10 medium in 
the presence of a simulated vaccine formulation. Vaccine treatments were prepared via the addition of 8 μM 
Aβ42 and 25 or 12.5 μg/mL ABA to complete R10 medium. Following 21 h incubation at 37 °C, 20 μM ThT and 
100 μM lumogallion was added to the respective treatments and incubated for a further 3 h, prior to their 1:1 
addition to THP-1 cells. Cells co-cultured for 24 h with simulated vaccine treatments contained 4 μM Aβ42 and 
(a–d) 12.5 μg/mL Alhydrogel® (Brenntag), (e–h) 12.5 μg/mL Imject Alum™ (Pierce, Thermo Scientific) or (i–l) 
6.25 μg/mL Adju-Phos® (Brenntag). Cells were fixed in 4% w/v PFA, washed in 50 mM PIPES buffer, pH 7.4 
before mounting with Fluoromount™ (Sigma Aldrich) on poly-lysine coated slides. Lumogallion (orange) (a,e 
and i) and ThT (blue) fluorescence (b,f and j) is depicted (Olympus single bandpass U-WMBV2 filter cube) 
with magnified inserts denoted (*). Merged lumogallion and ThT channels (c,g and k), combined with the light 
overlay (d,h and l) are also depicted. Arrows highlight discreet adjuvant particles. Magnification X 1000, scale 
bars: 20 μm.
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Finally, analyses of THP-1 cells co-cultured with Adju-Phos® in the presence of Aβ42 revealed the clear pres-
ence of positively stained amorphous aggregates in endosomal-like compartments (Fig. 4c). While particulate 
ABA was clearly contained intracellularly, classical negative staining of fibrillar amyloid was elusive. However, 
fibril-like projections formed between adjacent particulates were identified contained within the cytoplasm of 
THP-1 cells.
Discussion
We have investigated the fate of amyloid as a model antigen in a cellular model of vaccination. Through the use 
of direct fluorescent labelling, the intracytoplasmic accumulation of Aβ42 propagating as β-sheets was found in a 
monocytic THP-1 cell line. The use of ThT as a conformation-specific fluorophore for β-sheets of Aβ42 revealed 
that cytosolic loading of the amyloidogenic peptide occurred within 1 h and persisted intracellularly over 24 h, as 
revealed by a green intracellular fluorescence emission24.
A recent study monitoring the cellular uptake of Aβ42 identified the clathrin-independent endocytic route of 
macropinocytosis that allowed for the entry of the amyloidogenic peptide into a neuroblastoma SH-SY5Y cell 
line21. As a known pathway for the cellular uptake of protein antigens, solute molecules and nutrients, internali-
sation via this route is rapid as with phagocytosis occurring within minutes upon exposure to cultured cells29,30. 
The subsequent fusing of macropinocytotic vesicles with late lysosomes results in an acidic protease-rich environ-
ment, capable of degrading their vesicular cargo30.
As a high resolution and complementary technique to fluorescence microscopy, TEM of sectioned THP-1 
cells successfully identified intracytoplasmic negatively stained amyloid fibrils. Interestingly, while the latter has 
been shown intraneuronally in vivo, their enclosure in endosomal-like vesicles was not observed under the dosing 
regimen utilised herein20,31. Therefore, our results indicate the absence of mature autophagolysosomes, typically 
demonstrated through the presence of membrane-enclosed vesicles via TEM27,31.
In support of our new findings, recent studies have shown that while the cellular uptake of amyloid fibrils 
mechanistically initiates autophagy, the resultant degradation of amyloid is hindered through rupturing of lyso-
somal compartments32,33. Han et al., (2017) employed scanning transmission electron microscopy (STEM) that 
revealed the intracellular tomography of fibrillar assemblies of Aβ40 in THP-1 cells. Therein, pre-incubation of the 
peptide (20 μM) with non-differentiated THP-1 cells for 48 h, resulted in bundles of amyloid fibrils penetrating 
tubular invaginations of the phospholipid bilayer32. Such was further supported through increases in propidium 
iodide fluorescence upon binding to extracellular DNA, released upon perforation of the plasma membrane. 
Lysosomal leakiness of THP-1 cells was subsequently confirmed upon co-culture with Aβ40, indicated via the 
reduction of acridine orange upon release from acidified vesicles to the cell cytoplasm32.
Figure 4. Representative electron micrographs from TEM of Spurr resin-sectioned (100 nm sections) THP-1 
cells co-cultured with simulated vaccine formulations. Cells were co-cultured for 24 h in R10 medium with 
4 μM Aβ42 in the presence of 50 μg/mL Alhydrogel® (Brenntag Biosector, Denmark) (a and d), Imject™ Alum 
(Pierce, Thermo Scientific) (b and e) or Adju-Phos® (Brenntag, Denmark) (c and f). ThT and lumogallion 
at 10 and 50 μM respectively, were added at 21 h, as with fluorescence analyses of THP-1 ABA co-cultures. 
Cell resin-sections were stained for 20 min with 2% w/v ethanolic uranyl acetate, rinsed with 30% v/v ethanol 
followed by ultrapure water. Grids containing sections were allowed 24 h drying time prior to analysis via TEM. 
Inserts show close-ups of intracellular negatively stained amyloid (red arrows) co-deposited with ABA (black 
arrows) within the respective cell images. Magnification & scale bars: (a–c) X 30 K, 1 μm, (d–f) X 100 K, 0.2 μm, 
respectively.
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More recently, fibrillar forms of the Parkinson’s disease (PD) related amyloidogenic protein, α-synuclein, were 
found to induce rupture of intracellular vesicles, following endocytosis33. Interestingly, amyloid fibrils produced 
from both wild-type and mutant familial related variants of the protein were observed to rupture lysosomal vesi-
cles whether co-cultured with neuroblastoma SH-SY5Y or human dopaminergic neuronal cell lines. Vesicle rup-
ture of the former was also noted when co-cultured with the human AD-related microtubule-associated protein, 
tau33. Therefore the propensity of all amyloidogenic proteins to undergo structural conversion from their soluble 
native α-helical form to a conformation rich in β-sheet structure, pre-disposes their fibrillar structure to rupture 
intracellular lysosomal vesicles upon uptake32,33.
Aβ42 of increasing size was additionally identified in a β-pleated sheet conformation within cell nuclei over 
prolonged incubation periods. The presence of nuclear inclusions containing amyloid in neurodegenerative dis-
orders has revealed co-localisation of the eukaryotic protein, ubiquitin17,34. As an important initiator of the pro-
teasomal machinery in intracellular environments, covalent conjugation of the protein to misfolded proteins 
would normally lead to their degradation, in vivo17. In AD, ubiquitin is known to persist in such nuclear protein 
inclusion bodies of which the accumulation of long-chain ubiquitin molecules only has been shown to form 
amyloid-like fibrils, potentially exacerbating the condition17.
The persistence of intracytoplasmic or intranuclear amyloid may also be explained through disruptions in 
protein homoeostasis31. The mammalian target of rapamycin complex 1 (mTORC1) is a key regulator of auto-
phagy of which its inactivation allows for nutrient metabolism and the removal of non-functional and misfolded 
proteins35. In AD however, downstream mTORC1 signalling through phosphoinositide-3-kinase (PI3K), leads 
to the accumulation of autophagic vacuoles36. Therefore, our observation of cellular accumulation of the peptide 
antigen only depositing as mature amyloid fibrils, possibly owed to the inability of THP-1 cells to degrade these 
aberrant deposits.
The direct fluorescent labelling of a model Aβ42 peptide antigen formulated in the presence of clinically rele-
vant and experimental ABA preparations revealed their co-localisation in the cytosol of THP-1 cells. Lumogallion 
is an established and sensitive fluorescent molecular probe for the identification of aluminium in both cells and 
tissues and was utilised herein to monitor the fate of ABA, co-adsorbed to its target peptide antigen28,37,38. The 
complementary technique of TEM supported the observations from fluorescence microscopy, revealing the 
co-uptake of ABA and aggregates of β-pleated sheet amyloid antigen materials, in sectioned THP-1 cells.
Furthermore, TEM confirmed the presence of needle-like crystals of Alhydrogel®, plate-like aggregates of 
Adju-Phos® and amorphous deposits of Imject Alum™, all found enclosed within endosomal intracellular com-
partments. Therefore, the cellular uptake of both the clinically approved and experimental adjuvant formulations 
was in agreement with our previous work, even when coadministered with a model Aβ42 peptide antigen27.
Negatively stained amyloid fibrils of the model antigen were clearly distinguishable in cell cytosol when 
co-administered with Alhydrogel® and Imject Alum™. Interestingly, mature fibrillar aggregates co-deposited 
with Alhydrogel® or directly attached to Imject Alum® were identified on the periphery of endocytosed partic-
ulate adjuvant materials. However, intracellular aggregates of mature Aβ42 were elusive in vaccine formulations 
adjuvanted with Adju-Phos® in which the potential co-localisation of amyloid fibrils and ABA could only be 
detected at higher magnifications.
Intracytoplasmic vesicles noted for Aβ42 formulated in the presence of ABA, indicated that endocytosis was 
the most likely route of entry through autophagic processing to lysosomes27,37,39. As with THP-1 cells co-cultured 
with Aβ42 only however, mature amyloid fibrils whether co-localised or co-adsorbed to their target ABA, were 
not observed to enter endosomal-like vesicles. Therefore, cellular uptake of Aβ42 as a model peptide antigen and 
ABA are suggested to be internalised via the differing endocytic pathways of macropinocytosis and autophagy, 
respectively21,29,32,33. To our knowledge, this is the first report of the apparent lack of lysosomal vesicular enclosure 
of the pathogenic Aβ42 species in a simulated cell-based vaccination model of AD.
The thermodynamic saturation constant of Aβ42 predicts that spontaneous amyloid fibril formation occurs at 
concentrations at or exceeding 2 μM40. As such, catalysis of Aβ through metal interactions, glycoprotein binding 
and seeding have been implicated in the induction of auto polymerisation of nanomolar concentrations of the 
peptide, typically found in vivo40–42.
Furthermore, templating of soluble Aβ40 in vitro has been found to undergo polymerisation to a mature fibril-
lar form, upon the addition of brain extracts containing amyloid fibrils from transgenic AD mice42.
More recently, corrupting of host Aβ in vivo in the brains of transgenic murine models of AD has been demon-
strated through intracerebral inoculation with brain extracts containing fibrillar amyloid8,43. Interestingly, Aβ 
injected intraperitoneally was found to elicit a Trojan horse like mechanism, delivering Aβ as seeds to the brain 
of transgenic murine models of AD8. Regardless of the mechanism by which self-aggregation occurs, repeated 
nucleation of the soluble alpha-helical form of the peptide through nucleation-driven seeding results in the 
self-propagation of amyloid to a conformation rich in β-sheet structure1,3,18.
Therefore, our results support the uptake and potential transport of amyloid in a β-pleated sheet conformation 
that persists intracellularly, speculatively through lysosomal degradation32,33 accumulating and propagating as 
plaque-like fibrillar deposits. Circulating blood-borne monocytes are known to enter the central nervous system 
(CNS) in response to neuroinflammation and are thought to promote tissue repair and support the production 
of neurotrophic growth factors44. The intracellular persistence of mature amyloid fibrils through evasion of auto-
phagy or proteasomal-degradation mechanisms may therefore also allow for the silent entry of fibrillar amyloid 
across the blood-brain barrier (BBB).
Monocytes are one of the first phagocytic antigen presenting cell (APC) types to be recruited to the site of 
injection, following vaccination45. As such, mechanisms governing the immunoreactivity and cellular fate of 
amyloid may prove key in the development of vaccination regimes targeting these aberrant deposits. In sum-
mary, we herein demonstrate the ability for β-pleated sheet-rich amyloid fibrils to persist intracellularly, of which 
their translocation away from the injection site could be enhanced in the presence of clinically relevant ABA. 
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Alhydrogel® has previously been demonstrated as a more effective adjuvant for translocation away from the injec-
tion site, through its heightened cellular loading in THP-1 cells versus Adju-Phos®. The apparent lack of mature 
amyloid fibrils found for cells co-cultured with the latter would further implicate such in vivo27.
In conclusion, we have demonstrated the use of direct fluorescent labelling in the cellular monitoring of amy-
loid when administered in simulated vaccine formulations. The ability to detect both an intracellular amyloid 
antigen and its co-adsorbed ABA following their internalisation, provide proof of concept for the transport of 
both fluorophores across the cell membrane of THP-1 cells37. Furthermore, the conformation-specific fluoro-
phore, ThT, clearly demonstrated the cellular persistence of misfolded amyloid deposits in both cytosolic and 
nuclear inclusions. Overall, direct fluorophore-labelling and high-resolution TEM approaches omitting usual 
lead citrate staining may provide invaluable tools in the assessment of existing and future vaccinations directed 
against amyloid and other relevant neuropathological hallmarks of wider dementia.
Methods
Preparation of Aβ42 stock solutions. All chemicals were purchased from Sigma Aldrich, UK unless 
otherwise stated. The amyloidogenic peptide, Aβ42 was purchased from Bachem as the lyophilised salt and was 
reconstituted in 0.01 M NaOH to prepare 100 μM stocks. Under these highly alkaline conditions (ca pH 12), the 
fully dissolved peptide only exists in a monomeric form25,46. Subsequent stock solutions were aliquoted and stored 
frozen (−20 °C) and the peptide was thawed fully, immediately prior to use. Peptide concentrations in the final 
stock solutions were determined prior to their dilution in complete R10 medium. Briefly, thawed stocks were 
centrifuged at high speed (5 min, 15000 g) and their protein content determined using absorbance at 280 nm 
using a NanoDrop 1000 spectrophotometer (Thermo Scientific, UK). The final measured peptide concentration 
was adjusted based on percentage purity stated by the manufacturer and was used to prepare subsequent dilutions 
of Aβ42.
Preparation of simulated vaccine formulations. Herein, the clinically relevant aluminium based adju-
vants (ABA), Alhydrogel® (aluminium oxyhydroxide) and Adju-Phos® (aluminium hydroxyphosphate) were 
utilised (both from Brenntag Biosector, Denmark) in formulating simulated vaccines. Dilutions of the ABA were 
made in a simulated vaccine diluent of 0.9% w/v NaCl (autoclaved and sterile filtered through a 0.22 μm mem-
brane) at 1.0 mg/mL, of which further dilutions were made into the respective treatments27. Aβ42 was prepared 
in the absence or presence of a given ABA in R10 medium. Treatments were prepared aseptically in a cell culture 
hood and consisted of antigen only: 8 μM Aβ42, adjuvant only: 25.0 or 12.5 μg/mL ABA, or antigen and adjuvant. 
All treatments were incubated at 37 °C in a dedicated cell incubator for 24 h in order to promote amyloid fibril 
formation of Aβ42, prior to their addition to cells. Amyloid fibril formation was confirmed in R10 medium as 
described in the Supplemental methods.
Direct fluorescent pre-labelling of amyloid vaccine co-cultures. THP-1 cells were cultured to a den-
sity of 1.0 × 106 cells/mL of which 100 μL per well (ca 50,000 cells) were transferred into 96 well plates (TC treated, 
VWR, Corning Costar®) (see Supplemental methods). Cell viability was confirmed by use of the Trypan blue 
(Life Technologies, UK) exclusion test. Native THP-1 cells containing neither additional ABA nor antigen were 
diluted 1:1 with R10 medium. Pre-incubated treatments were diluted 1:1 with cells to a final volume of 200 μL, 
thereby providing simulated vaccines containing 4 μM Aβ42 antigen in the absence or presence of 12.5 or 6.25 μg/
mL ABA only, in the final co-culture conditions.
Initial experiments, monitoring the cellular uptake of Aβ42 only (longpass emission), were formulated in R10 
medium containing 20 μM ThT at T = 0. Subsequent treatments prepared in this manner were added to THP-1 
cells following 24 h incubation. Experiments utilising treatments containing both Aβ42 and an additional ABA 
were plated with THP-1 cells and incubated for 21 h at 37 °C (5% CO2). Dyes for pre-labelling utilised thioflavin T 
(ThT) at 100 μM and lumogallion at 1 mM, both prepared in ultrapure water and filtered through 0.22 μm syringe 
filters. ThT and lumogallion were added to cells co-cultured with simulated vaccine treatments at a final concen-
tration of 10 and 50 μM respectively and treated cells were incubated for a further 3 h, prior to fixation.
Fluorescence microscopy. Whole non-sectioned THP-1 cells were prepared on poly-lysine coated slides, 
as described in the Supplemental methods. Fluorescence micrographs were obtained by use of an Olympus BX50 
microscope equipped with a BX-FLA reflected light fluorescence attachment (mercury source) and a vertical illu-
minator. Micrographs obtained at X 1000 magnification utilised an X 100 Plan-Fluorite oil immersion objective 
(Olympus, UK) using low auto-fluorescence immersion oil (Olympus immersion oil type-F).
Fluorescence filter cubes utilised a U-MNIB3 cube (excitation: 470–495 nm, dichromatic mirror: 505 nm, 
Olympus, UK) with the emission filter swapped for a single bandpass ET590/33 m filter (emission: 570–610 nm, 
Chroma®, Vermont, US) for lumogallion imaging. ThT-reactive amyloid was imaged using a U-MWBV2 cube in 
long bandpass mode utilising the original mirror unit (excitation: 400–440 nm, dichromatic mirror: 455 nm, long-
pass emission filter: 475 nm) and in single bandpass mode utilising an ET480/30 m filter (emission: 470–500 nm, 
Chroma®, Vermont, US). Light transmission values were fixed (1000 ms) across respective treatment conditions 
and images were acquired using the CellD (Olympus, Soft Imaging Solutions, GmbH) software package.
Transmission electron microscopy. Spurr-resin embedded agar-cell blocks were sectioned using cut glass 
knives at 90 nm, by use of an automated REICHERT-JUNG Ultracut E ultramicrotome. Any sections containing 
ABA materials were sectioned at 100 nm by use of a Leica ultracut UCT ultramicrotome, equipped with a 45° 
Diatome diamond knife (30-US, Electron Microscopy Sciences). Sections were mounted on G2002 200 mesh thin 
bar copper grids (Athene, Agar Scientific, UK), pre-treated with a COAT-QUICK “G” grid coating pen (Daido 
Sangyo Co. Ltd. Japan) for adherence. Grids were allowed 24 h drying time prior to analysis. Cell sections for 
TEM were viewed on a JEOL 1230 transmission electron microscope operated at 100 kV (spot size 1). A 10 μA 
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activated field emission was used to increase the standing current to 67–68 μA during image acquisition. Electron 
micrographs were captured using a Megaview III digital camera from Soft Imaging Systems (SiS), using the iTEM 
universal TEM imaging platform software.
Data availability. All data generated or analysed during this study are included in this published article and 
its Supplementary Information files.
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